However, I rarely write about what happens after an Advisory Committee (Adcom) makes a decision. In the case of Progenics ( PGNX ), I believe that the Adcom has just handed down a significant decision that will help the company (should the FDA adopt it
By Bret Jensen : I have found some of my biggest winners have come from small cap stocks selling for less than $5 a share. These companies receive scant analyst coverage, and one must do the research to uncover hidden gems. I personally look at myriad factors when analyzing the space. Insider ...
Progenics Pharmaceuticals ( PGNX +9.2% ) CEO Mark Baker will comment tomorrow in a conference call on the FDA's Anesthetic and Analgesic Drug Products Ad
the FDA, would potentially mitigate a time-consuming and expensive hurdle for the drug makers in their NDA application efforts. Related tickers: ( CBST -0.6% ) ( NKTR ) ( SLXP +3.2% ) ( THRX -2.4% ) ( PGNX ) Post your comment!
The NASDAQ halts trading of Progenix Pharmaceuticals ( PGNX ) while the FDA's Anesthetic and Analgesic Drug Products Ad Comm meets today and tomorrow to discuss the potential cardiovascular
Top gainers, as of 5:15 p.m.: KANG +4.5% . PGNX +3.0% . ONNN +2.3% . TPLM +2.3% . SNMX +2.2% . Top losers, as of 5:15 p.m.: CASY -3.0% . SMCI -2.6% . MCK -2.5% . IMS -2.4% . REED -2.2% . Post your comment!
By Scott Matusow : Written by Scott Matusow. Coming up on June 10th, 2014, Orexigen Therapeutics ( OREX ) expects a Food and Drug Administration (FDA) decision concerning its weight loss drug, NB32 (Contrave). Contrave was initially rejected by the FDA due to a single issue cardiovascular safety ...
biotech map a bit in the beginning of 2014, but has a chance to regain investor interest in the near term. Progenics Pharmaceuticals ( PGNX ) is a biotechnology company that focuses on developing oncology and therapeutics worldwide. At this time
Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more
(Reuters) - Shares of Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals tumbled after U.S. health regulators declined to approve wider use of their drug for opioid-induced constipation and...